Crutch for the Heart

Crutch for the Heart

Andre Willers

23 Sep 2013

This is definitely not medical advice .

Synopsis :

A stressed heart must rest , but still support oxidation processes . Rest and increased metabolic efficiency are needed .

 

Discussion :

1.Increased metabolic efficiency = reduced drag on heart .

1.1 EPO .

A pulse of EPO switches on increased mitochondrial activity , including transport mechanisms .

This increases the efficiency of the general metabolism by up to a whopping 50% .

This enables the heart muscles to rest and repair themselves .

The most effective intervention .

 

1.2 Q10 and Hawthorn

Also increases metabolic efficiency , but not nearly as much as EPO .

1.3 MSM

Needed for any cellular repair .

1.4 Arthritic antibodies

See Appendix A

The flaps of the heart-valves are joints , too . The same compression/uncompression  waves as limbs . Extreme acceleration .

Auto-immune diseases get triggered by acceleration moving cytochromes from off the histone , that enables expression of genes out of sequence . The immune system treats this as a foreign object . (It’s dumb , but not that dumb) .

It then attacks the source of the acceleration .

 

What we need is a Tai Chi of the heart .

See Appendix B .

Or swimming mildly (no butterfly strokes)

   

2.Will ARV’s help ?

Probably .

The probability is 67% that the immune system roped in attack viruses to help with auto-immune affairs .

It is like getting in an outside agency to deal with corruption in the police force . ARV’s will help with these .

Flu-like viruses are the system’s preferred way of transferring information .

 

Hope this helps

Regards

Andre

Xxxxxxxxxxxxxxxxxxxxxxxxx

Appendix A

http://www.newscientist.com/article/mg21729055.400-synthetic-llama-antibodies-soothe-arthritis-pain.html#.UkCjpYZRok0

Synthetic llama antibodies soothe arthritis pain

·         22 February 2013 by Andy Coghlan

·         Magazine issue 2905. Subscribe and save

ARTHRITIS may have met its match, in the form of the llama immune system. Antibodies similar to ones originally discovered in camels and llamas have helped to heal moderate to severe arthritis in a small trial.

The antibodies have inspired the design of a drug, ALX-0061, that blocks a receptor for interleukin 6. This signalling molecule amplifies inflammation, leading to sore and swollen joints. The symptoms ease once the receptor is blocked.

In the trial, 24 patients received one of three unchanging doses of ALX-0061 for six months. Another group received a placebo. Sixty-three per cent of those given the drug saw their symptoms practically vanish when measured using a standard metric, the DAS28 scale, which evaluates symptoms in 28 joints. This figure is more than twice the 30 per cent remission rate seen with the current "gold-standard" rival treatment Actemra (tocilizumab). Tocilizumab also targets interleukin 6, but it is based on a normal-sized mammalian antibody.

The remission rate was even higher – 75 per cent – for the eight patients given one of the three doses: 3 milligrams per kilogram of body weight administered once every four weeks. "These data suggest that out of every 10 patients, seven to eight could experience rapid, durable responses to their symptoms," says Josi Holz, the chief medical officer of Ablynx, in Ghent, Belgium, whichreleased its results on 13 February.

According to Ed Moses, CEO of Ablynx, it could be the tiny size of the molecule – one-fifth the usual size – that gives it the edge over existing antibody-based treatments. "It potentially gives far faster and deeper penetration of diseased joints," he says.

Other researchers caution against over-optimism because the trial was short and small. "If the results are repeated in randomised, controlled, double-blinded studies, then they would be very impressive," says David Scott, chief medical adviser to the UK's National Rheumatoid Arthritis Society.

To take ALX-0061 forward, Ablynx is now looking for a partner to help finance such a larger, decisive trial.

Xxxxxxxxxxxxxxxxxxxxxxxxxx

Appendix B

http://www.ncbi.nlm.nih.gov/pubmed/18487898

Tai Chi training for patients with coronary heart disease.

Lan C, Chen SY, Wong MK, Lai JS.

Source

Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital and College of Medicine, National Taiwan University, 7 Chung-Shan South Road, Taipei, Taiwan, ROC. clan@ntu.edu.tw

Abstract

Coronary heart disease (CHD) is the leading cause of death in the developed countries and many developing countries. Exercise training is the cornerstone of cardiac rehabilitation program for patients with CHD, and exercise intensities in the 50-70% heart rate reserve have been shown to improve functional capacity. However, recent studies found exercise with lower intensity also displayed benefits to CHD patients, and increased the acceptance of exercise program, particularly unfit and elderly patients. Tai Chi Chuan (TC) is a traditional conditioning exercise in the Chinese community, and recently it has become more popular in the Western societies. The exercise intensity of TC is low to moderate, depending on the training style, posture and duration. Participants can choose to perform a complete set of TC or selected movements according to their needs. Previous research substantiates that TC enhances aerobic capacity, muscular strength, endothelial function and psychological wellbeing. In addition, TC reduces some cardiovascular risk factors, such as hypertension and dyslipidemia. Recent studies have also proved that TC is safe and effective for patients with myocardial infarction, coronary bypass surgery and heart failure. Therefore, TC may be prescribed as an alternative exercise program for selected patients with cardiovascular diseases. In conclusion, TC has potential benefits for patients with CHD, and is appropriate for implementation in the community.

xxxxxxxxxxxxxxxxxxxxxxxxxxx